Skip to main content
Clinical Trials/JPRN-UMIN000003992
JPRN-UMIN000003992
Completed
Phase 3

RCT of Tri-Modalities with I-125 Brachy Therapy and EBRT and Short or Long Term Hormone Therapy for High-risk Localized Prostate Cancer - RCT of Tri-Modalities with I-125 Brachy Therapy and EBRT and Short or Long Term Hormone Therapy for High-risk Localized Prostate Cancer (TRIP Study)

Kanazawa University Translational Research Informatices Center0 sites340 target enrollmentAugust 5, 2010
ConditionsProstate Cancer

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Kanazawa University Translational Research Informatices Center
Enrollment
340
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 5, 2010
End Date
September 1, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Kanazawa University Translational Research Informatices Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients who have active double cancer 2\) Patients with poorly controlled hypertension (i.e., diastolic blood pressure\>\=120 mm Hg) 3\) Patients with severe psychiatric disorders 4\) Patients with collagen diseases 5\) Patients with poorly controlled diabetes 6\) Patients with poorly controlled ischemic cardiac disease 7\) Patients who had prior surgery for prostate (transurethral prostatectomy, radical prostatectomy, orchiectomy, other surgery for BPH and/or hyperthermia) 8\) Patients who had brachytherapy and/or EBRT 9\) Patients who are taking steroid drugs (except for ointment) 10\) Patients who are taking other antiandrogen for BPH 11\) Patients who had CAB for more than 3 months prior to the registration 12\) Patients who are judged inappropriate for the clinical trial by doctors

Outcomes

Primary Outcomes

Not specified

Similar Trials